Qi Huo Ri Bao·2025-12-02 14:57Group 1: Market Performance - The A-share market experienced rapid rotation of hot themes, with the Shanghai Composite Index down 0.42%, the Shenzhen Component Index down 0.68%, and the ChiNext Index down 0.69% at the close [1] - The total market turnover reached 1,607.3 billion [1] Group 2: Sector Performance - The pharmaceutical commercial sector showed strong performance, ranking first in the increase of sector shares, with Haiwang Biological achieving a "five consecutive limit-up" and over 290,000 sealed orders remaining at the limit-up price [1] - The Fujian sector also performed well, with stocks like Jiarong Technology and Haixin Food hitting limit-up prices [1] - Energy metals and film industry sectors, which performed well previously, experienced adjustments [1] Group 3: Market Outlook - The market is expected to remain in a phase of frequent style switching in December, primarily characterized by structural trends [1] - Key areas for potential deployment include technological innovation, domestic demand expansion, anti-involution, and stabilizing the real estate sector, with industry meetings likely to catalyze thematic trends [1] - External uncertainties, particularly the potential impact of the upcoming Federal Reserve meeting on global market liquidity, are also highlighted [1] Group 4: Health Sector Insights - The China CDC reported that the flu positivity rate among emergency and outpatient cases is close to 45%, indicating a rapid increase in flu cases, with some provinces reaching high epidemic levels [2] - According to Everbright Securities, the demand for cold medicines in Q4 is expected to exceed market expectations due to the rising trend of flu cases [2] - The introduction of multi-pathogen detection products and convenient diagnostic tools is anticipated to support the performance of related pharmaceutical companies [2]